Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8514390rdf:typepubmed:Citationlld:pubmed
pubmed-article:8514390lifeskim:mentionsumls-concept:C0026809lld:lifeskim
pubmed-article:8514390lifeskim:mentionsumls-concept:C0021745lld:lifeskim
pubmed-article:8514390lifeskim:mentionsumls-concept:C1817882lld:lifeskim
pubmed-article:8514390lifeskim:mentionsumls-concept:C0205263lld:lifeskim
pubmed-article:8514390lifeskim:mentionsumls-concept:C0205224lld:lifeskim
pubmed-article:8514390lifeskim:mentionsumls-concept:C0205227lld:lifeskim
pubmed-article:8514390lifeskim:mentionsumls-concept:C0026930lld:lifeskim
pubmed-article:8514390pubmed:issue7lld:pubmed
pubmed-article:8514390pubmed:dateCreated1993-7-22lld:pubmed
pubmed-article:8514390pubmed:abstractTextThe present study examined the role of endogenous gamma interferon (IFN-gamma) in the formation of granulomas in mice which had been given a single intravenous injection of glycolipid-containing mycolic acid (trehalose 2,3,6'-trimycolate) purified from cell walls of Rhodococcus aurantiacus (Gordona aurantiaca) (GaGM) in the form of liposome. The histological status of granuloma formation in the livers, spleens, and lungs of GaGM-injected mice was studied at weeks 1 through 5, and the titers of endogenous IFN-gamma in all of these organ extracts and in the sera were determined by enzyme-linked immunosorbent assay. The granulomas, composed of epithelioid cells, developed until 3 weeks postinjection, and thereafter the granulomas regressed. The production of endogenous IFN-gamma was biphasic, with an early phase detected at days 1 through 3 and a late phase detected at weeks 1 through 5. The latter peak of endogenous IFN-gamma production proceeded in parallel with granuloma formation. Both the areas of granulomas and titers of IFN-gamma in these organs were dependent on the doses of GaGM used for injection. The cells which produce endogenous IFN-gamma in the spleens appear within the granulomas. To study the role of endogenous IFN-gamma in granuloma formation, the in vivo administration of rat anti-mouse IFN-gamma monoclonal antibody was carried out. Anti-mouse IFN-gamma monoclonal antibody neutralized endogenous IFN-gamma and resulted in the suppression of the number of granulomas and the size of each granuloma. These findings suggest that biphasic production of endogenous IFN-gamma in the local lesions may be crucial to the formation and development of the granulomas.lld:pubmed
pubmed-article:8514390pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8514390pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8514390pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8514390pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8514390pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8514390pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8514390pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8514390pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8514390pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8514390pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8514390pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8514390pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8514390pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8514390pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8514390pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8514390pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8514390pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8514390pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8514390pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8514390pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8514390pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8514390pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8514390pubmed:languageenglld:pubmed
pubmed-article:8514390pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8514390pubmed:citationSubsetIMlld:pubmed
pubmed-article:8514390pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8514390pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8514390pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8514390pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8514390pubmed:statusMEDLINElld:pubmed
pubmed-article:8514390pubmed:monthJullld:pubmed
pubmed-article:8514390pubmed:issn0019-9567lld:pubmed
pubmed-article:8514390pubmed:authorpubmed-author:MinagawaTTlld:pubmed
pubmed-article:8514390pubmed:authorpubmed-author:NakanoKKlld:pubmed
pubmed-article:8514390pubmed:authorpubmed-author:AsanoMMlld:pubmed
pubmed-article:8514390pubmed:issnTypePrintlld:pubmed
pubmed-article:8514390pubmed:volume61lld:pubmed
pubmed-article:8514390pubmed:ownerNLMlld:pubmed
pubmed-article:8514390pubmed:authorsCompleteYlld:pubmed
pubmed-article:8514390pubmed:pagination2872-8lld:pubmed
pubmed-article:8514390pubmed:dateRevised2009-11-18lld:pubmed
pubmed-article:8514390pubmed:meshHeadingpubmed-meshheading:8514390-...lld:pubmed
pubmed-article:8514390pubmed:meshHeadingpubmed-meshheading:8514390-...lld:pubmed
pubmed-article:8514390pubmed:meshHeadingpubmed-meshheading:8514390-...lld:pubmed
pubmed-article:8514390pubmed:meshHeadingpubmed-meshheading:8514390-...lld:pubmed
pubmed-article:8514390pubmed:meshHeadingpubmed-meshheading:8514390-...lld:pubmed
pubmed-article:8514390pubmed:meshHeadingpubmed-meshheading:8514390-...lld:pubmed
pubmed-article:8514390pubmed:meshHeadingpubmed-meshheading:8514390-...lld:pubmed
pubmed-article:8514390pubmed:meshHeadingpubmed-meshheading:8514390-...lld:pubmed
pubmed-article:8514390pubmed:meshHeadingpubmed-meshheading:8514390-...lld:pubmed
pubmed-article:8514390pubmed:meshHeadingpubmed-meshheading:8514390-...lld:pubmed
pubmed-article:8514390pubmed:year1993lld:pubmed
pubmed-article:8514390pubmed:articleTitleEndogenous gamma interferon is essential in granuloma formation induced by glycolipid-containing mycolic acid in mice.lld:pubmed
pubmed-article:8514390pubmed:affiliationDepartment of Microbiology, School of Medicine, Hokkaido University, Sapporo, Japan.lld:pubmed
pubmed-article:8514390pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8514390lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8514390lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8514390lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8514390lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8514390lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8514390lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8514390lld:pubmed